158 related articles for article (PubMed ID: 34960901)
21. Sulfobutylether-β-cyclodextrin/chitosan nano- and microparticles and their physicochemical characteristics.
Fülöp Z; Saokham P; Loftsson T
Int J Pharm; 2014 Sep; 472(1-2):282-7. PubMed ID: 24971695
[TBL] [Abstract][Full Text] [Related]
22. Enhancement of Valsartan Oral Bioavailability by Preparing a Microwave-Irradiated Inclusion Complex with Sulfobutyl Ether β-Cyclodextrin Using a Central Composite Face Design for Optimising Process Parameters.
Maddula VR; Dachuru RSR
AAPS PharmSciTech; 2023 May; 24(5):115. PubMed ID: 37160765
[TBL] [Abstract][Full Text] [Related]
23. Drug-in-cyclodextrin-in-polymeric nanoparticles: A promising strategy for rifampicin administration.
Abruzzo A; Croatti V; Zuccheri G; Pasquale Nicoletta F; Sallustio V; Corazza E; Vitali B; Cerchiara T; Luppi B; Bigucci F
Eur J Pharm Biopharm; 2022 Nov; 180():190-200. PubMed ID: 36210035
[TBL] [Abstract][Full Text] [Related]
24. Mathematical modelling of the transport of hydroxypropyl-β-cyclodextrin inclusion complexes of ranitidine hydrochloride and furosemide loaded chitosan nanoparticles across a Caco-2 cell monolayer.
Sadighi A; Ostad SN; Rezayat SM; Foroutan M; Faramarzi MA; Dorkoosh FA
Int J Pharm; 2012 Jan; 422(1-2):479-88. PubMed ID: 22101294
[TBL] [Abstract][Full Text] [Related]
25. Self-assembly of cyclodextrin complexes: aggregation of hydrocortisone/cyclodextrin complexes.
Messner M; Kurkov SV; Brewster ME; Jansook P; Loftsson T
Int J Pharm; 2011 Apr; 407(1-2):174-83. PubMed ID: 21237259
[TBL] [Abstract][Full Text] [Related]
26. Intranasal administration of brain-targeted HP-β-CD/chitosan nanoparticles for delivery of scutellarin, a compound with protective effect in cerebral ischaemia.
Liu S; Ho PC
J Pharm Pharmacol; 2017 Nov; 69(11):1495-1501. PubMed ID: 28809432
[TBL] [Abstract][Full Text] [Related]
27. Antioxidant, antibacterial and anti-cancer activities of β-and γ-CDs/curcumin loaded in chitosan nanoparticles.
Alizadeh N; Malakzadeh S
Int J Biol Macromol; 2020 Mar; 147():778-791. PubMed ID: 31982535
[TBL] [Abstract][Full Text] [Related]
28. Release Characteristics of an Essential Oil Component Encapsulated with Cyclodextrin Shell Matrices.
Li Z; Wen W; Chen X; Zhu L; Cheng G; Liao Z; Huang H; Ming L
Curr Drug Deliv; 2021; 18(4):487-499. PubMed ID: 32735520
[TBL] [Abstract][Full Text] [Related]
29. Mesalazine/hydroxypropyl-β-cyclodextrin/chitosan nanoparticles with sustained release and enhanced anti-inflammation activity.
Tang P; Sun Q; Zhao L; Pu H; Yang H; Zhang S; Gan R; Gan N; Li H
Carbohydr Polym; 2018 Oct; 198():418-425. PubMed ID: 30093018
[TBL] [Abstract][Full Text] [Related]
30. Development of a Chitosan-based Nanoparticle Formulation for Ophthalmic Delivery of Honokiol.
Deng F; Hu W; Chen H; Tang Y; Zhang L
Curr Drug Deliv; 2018; 15(4):594-600. PubMed ID: 28425869
[TBL] [Abstract][Full Text] [Related]
31. In Silico design of AVP (4-5) peptide and synthesis, characterization and in vitro activity of chitosan nanoparticles.
Kecel-Gunduz S; Budama-Kilinc Y; Cakir-Koc R; Zorlu T; Bicak B; Kokcu Y; E Ozel A; Akyuz S
Daru; 2020 Jun; 28(1):139-157. PubMed ID: 31942695
[TBL] [Abstract][Full Text] [Related]
32. Cyclodextrins.
Stella VJ; He Q
Toxicol Pathol; 2008 Jan; 36(1):30-42. PubMed ID: 18337219
[TBL] [Abstract][Full Text] [Related]
33. Role of Cyclodextrins in Nanoparticle-Based Drug Delivery Systems.
Shelley H; Babu RJ
J Pharm Sci; 2018 Jul; 107(7):1741-1753. PubMed ID: 29625157
[TBL] [Abstract][Full Text] [Related]
34. Enhanced solubility of guanosine by inclusion complexes with cyclodextrin derivatives: Preparation, characterization, and evaluation.
Mohandoss S; Atchudan R; Immanuel Edison TNJ; Mandal TK; Palanisamy S; You S; Napoleon AA; Shim JJ; Lee YR
Carbohydr Polym; 2019 Nov; 224():115166. PubMed ID: 31472864
[TBL] [Abstract][Full Text] [Related]
35. Development and Characterization of Gefitinib Loaded Polymeric Nanoparticles by Ionic Gelation Method.
Gupta M; Marwaha RK; Dureja H
Pharm Nanotechnol; 2017; 5(4):301-309. PubMed ID: 28982345
[TBL] [Abstract][Full Text] [Related]
36. Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation.
Devasari N; Dora CP; Singh C; Paidi SR; Kumar V; Sobhia ME; Suresh S
Carbohydr Polym; 2015 Dec; 134():547-56. PubMed ID: 26428157
[TBL] [Abstract][Full Text] [Related]
37. Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery.
Rukmangathen R; Yallamalli IM; Yalavarthi PR
Drug Dev Ind Pharm; 2019 Aug; 45(8):1342-1350. PubMed ID: 31094571
[No Abstract] [Full Text] [Related]
38. Sulfobutyl ether(7) β-cyclodextrin (SBE(7) β-CD) carbamazepine complex: preparation, characterization, molecular modeling, and evaluation of in vivo anti-epileptic activity.
Jain AS; Date AA; Pissurlenkar RR; Coutinho EC; Nagarsenker MS
AAPS PharmSciTech; 2011 Dec; 12(4):1163-75. PubMed ID: 21918921
[TBL] [Abstract][Full Text] [Related]
39. Treatment of oxidative stress-induced pain and inflammation with dexketoprofen trometamol loaded different molecular weight chitosan nanoparticles: Formulation, characterization and anti-inflammatory activity by using in vivo HET-CAM assay.
Öztürk AA; Kıyan HT
Microvasc Res; 2020 Mar; 128():103961. PubMed ID: 31758946
[TBL] [Abstract][Full Text] [Related]
40. Preparation and Biophysical Characterization of Quercetin Inclusion Complexes with β-Cyclodextrin Derivatives to be Formulated as Possible Nose-to-Brain Quercetin Delivery Systems.
Manta K; Papakyriakopoulou P; Chountoulesi M; Diamantis DA; Spaneas D; Vakali V; Naziris N; Chatziathanasiadou MV; Andreadelis I; Moschovou K; Athanasiadou I; Dallas P; Rekkas DM; Demetzos C; Colombo G; Banella S; Javornik U; Plavec J; Mavromoustakos T; Tzakos AG; Valsami G
Mol Pharm; 2020 Nov; 17(11):4241-4255. PubMed ID: 32986435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
